Paeoniflorin Protects Diabetic Mice Against Myocardial Ischemic Injury Via the Transient Receptor Potential Vanilloid 1/calcitonin Gene-Related Peptide Pathway.
Fei Han,Dongchen Zhou,Xiang Yin,Zewei Sun,Jie Han,Lifang Ye,Wengting Zhao,Yuanyuan Zhang,Zhen Wang,Liangrong Zheng
DOI: https://doi.org/10.1186/s13578-016-0085-7
2016-01-01
Cell & Bioscience
Abstract:BACKGROUND:Diabetes mellitus has multiple complications including neuropathy and increases cardiovascular events. Paeoniflorin (PF), a monoterpene glycoside, plays an essential role in neuroprotection and ischemic heart disease. In this study, we aimed to investigate the hypothesis that PF protects mice with diabetes mellitus against myocardial ischemic injury, and determine its associated mechanisms.RESULTS:Myocardial infarction (MI) was generated in the streptozotocin-mediated diabetic mice, which were pretreated with either vehicle or PF, respectively. Myocardial infarct size, myocardial enzyme, cardiac function, circulating calcitonin gene-related peptide (CGRP) concentration, histological analysis and the expression of associated molecules were determined and compared among different experimental groups. Compared to diabetic hearts pretreated with vehicle, hearts pretreated with PF exhibited less tissue damage and better CGRP concentration in serum when subjected to myocardial ischemia. Transient receptor potential vanilloid 1(TRPV1) gene knockout attenuated PF-mediated cardioprotection. Moreover, a specific Ca(2+)/calmodulin-dependent protein kinase (CaMK) inhibitor, KN-93, increased tissue damage and decreased CGRP activity in serum. Meanwhile, pretreated with PF increased the phosphorylation of cAMP response element binding protein (CREB).CONCLUSIONS:Taken together, these findings demonstrate that PF protects diabetic mice against MI at least partially via the TRPV1/CaMK/CREB/CGRP signaling pathway.